Skip to main content
Premium Trial:

Request an Annual Quote

Zeiss and Rosetta Inpharmatics Are Among Recent US Patent Winners

Premium

Chugai Seiyaku Kabushiki Kaisha has been awarded US Patent No. 6,855,507, “Method of screening for pharmaceuticals by detecting cross-talk between intracellular signals and intranuclear receptors.”

Inventors listed on the patent are Shigeaki Kato and Jun Yanagisawa.

According to its abstract, the patent protects a screening method and a molecular designing method for pharmaceuticals with identified site of action and higher specificity, under the knowledge that two kinds of intracellular signal transfer mechanisms of the TGF-beta super family receptor exist: A pathway via a Smad molecule, and a pathway via a novel MAP kinase such as TAB1 and TAK1; as well as the knowledge that the interaction of Smad with intranuclear receptor or CBP/p300 on transcription controlled by Smad.


Carl Zeiss Jena has been awarded US Patent No. 6,858,852, “Method and apparatus for rapid change of fluorescence bands in the detection of dyes in fluorescence microscopy.”

Inventors listed on the patent are Ralf Wolleschensky and Gunter Moehler.

According to its abstract, the patent protects a method for operation of an image-generating optical system for detection of characteristic quantities of the wavelength-dependent behavior of an illuminated specimen, such as the emission behavior and/or absorption behavior and, in particular, the fluorescence and/or luminescence and/or phosphorescence and/or enzyme-active light emission and/or enzyme-active fluorescence. Specifically, the patent discusses the operation of a laser scanning microscope, comprising the steps of splitting the image point information of the specimen into spectral components in a spatially resolved manner on the detection side in dependence on wavelength and carrying out at least one summing for different spectral components.


Rosetta Inpharmatics has been awarded US Patent No. 6,859,735, “Computer systems for identifying pathways of drug action.”

Inventors listed on the patent are Roland Stoughton and Stephen Friend.

According to its abstract, the patent protects methods and computer systems for identifying and representing the biological pathways of drug action on a cell. The patent also protects methods and computer systems for assessing the significance of the identified representation and for verifying that the identified pathways are actual pathway of drug action, the abstract states. The patent also protects methods and computer systems for drug development based on the methods for identifying biological pathways of drug action, and methods and computer systems for representing the biological pathways involved in the effect of an environmental change upon a cell, the abstract states.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.